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Although prolactin (pRL) and its receptor (pRLR) have been detected in glioblastoma multiforme 
(GBM), their role in its pathogenesis remains unclear. our aim was to explore their contribution in GBM 
pathogenesis. We detected pRL and pRLR in all GBM cell lines tested. pRLR activation or overexpression 
using plasmid transfection increased proliferation, viability, clonogenicity, chemoresistance and matrix 
metalloproteinase activity in GBM cells, while pRLR antagonist ∆1–9-G129R-hPRL reduced their 
proliferation, viability, chemoresistance and migration. Meta-analysis of transcriptomic data indicated 
that PRLR was expressed in all grade II-III glioma (GII-III) and GBM samples. PRL was upregulated in 
GBM biopsies when compared to GII-III. While in the general population tumour PRL/PRLR expression 
did not correlate with patient survival, biological sex-stratified analyses revealed that male patients 
with pRL+/PRLRHiGH GBM performed worse than pRL+/PRLRLoW GBM. in contrast, all male pRL+/
pRLRHiGH GII-III patients were alive whereas only 30% of PRL+/PRLRLoW GII-III patients survived after 
100 months. Our study suggests that PRLR may be involved in GBM pathogenesis and could constitute 
a therapeutic target for its treatment. Our findings also support the notion that sexual dimorphism 
should be taken into account to improve the care of GBM patients.
Gliomas are primary tumours of the central nervous system (CNS) that develop from glial cells. While grade I gli-
omas are non-infiltrative tumours that are usually cured with complete surgical resection, grade II-IV gliomas are 
highly invasive, which eventually leads to the death of the patients1. More than half of these gliomas are grade IV, 
otherwise known as glioblastomas multiforme (GBM), for which the overall 5-year survival rate remains below 
5%1. Many therapeutic challenges characterize GBM, i.e. the invasion within the non-neoplastic brain, which 
makes complete tumour resection virtually impossible; the intrinsic resistance of GBM cells to chemotherapy and 
radiotherapy; and the immunosuppressive microenvironment, which impairs the development of an adequate 
antitumour immune response. Thus, it is crucial to better understand the pathogenesis of this disease and to 
identify novel therapeutic targets that could improve the treatment of GBM patients.
Prolactin (PRL) is a peptide hormone primarily secreted by the anterior pituitary gland. Although PRL has 
been traditionally associated principally to the regulation of lactation and fertility, this hormone has been lately 
involved in the development of several types of cancer2,3. Extrapituitary sources of PRL include the mammary 
gland, prostate, brain, immune cells and skin, where this hormone acts as a paracrine/autocrine physiological 
regulator of tissue development and homeostasis. In addition, PRL and its receptor (PRLR) have been associated 
with the development of hormone-dependent tumours, such as breast and prostate cancer2,3. The expression of 
PRL and PRLR has been reported to be higher in breast and prostate cancer than in their healthy counterparts 
and has been associated with increased risk of breast and prostate cancer and treatment resistance2. PRL has also 
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been reported to promote tumour cell proliferation, angiogenesis4–6 and chemoresistance7,8. Although there is 
controversy on the role of PRL/PRLR in the pathogenesis of breast tumours3, blockade of PRLR has been pro-
posed to constitute a therapeutic approach for the treatment of hormone-dependent tumours, including breast 
cancer. Since extrapituitary expression of PRL is independent of dopamine regulation, the use of PRLR antago-
nists or neutralizing antibodies and small molecule inhibitors has been proposed as therapeutic alternatives for 
breast and prostate resistant tumours2,3.
In humans, various isoforms of the PRLR, i.e. long, intermediate and short, result from alternative splicing 
and vary in the length of the intracellular domain9. Since they encompass different signalling pathways, the rel-
ative expression of these receptors in normal and pathological tissues may explain, in part, the versatility of PRL 
actions reported in several tissues, such as the healthy and neoplastic mammary gland3. Although many reports 
have indicated that PRL and PRLR are present in GBM10–13, the role of the PRL/PRLR system in the pathogenesis 
of GBM remains poorly understood. The expression of PRL and PRLR has been detected in GBM biopsies by 
immunocytochemistry10–13. Furthermore, high levels of circulating PRL have been reported in ~30% of GBM 
patients in a relatively small clinical study11. The expression levels of the PRL gene have also been reported to 
be higher in GBM than in GII-III14. In addition, local expression of PRL and high levels of circulating PRL have 
been shown to correlate with the proliferation index and the vascular density of GBM11. PRL was reported to 
modulate the expression of intercellular adhesion molecules15 and to facilitate the migration of human GBM 
cells in vitro12. Activation as well as overexpression of PRLR have been shown to stimulate the proliferation of 
GBM cell lines in vitro16.
In order to shed light on the role of PRL and PRLR in the pathogenesis of GBM, we evaluated proliferation, 
viability, chemosensitivity and migration of GBM cells in response to PRL stimulation or PRLR signalling block-
ade using the receptor-specific antagonist ∆1–9-G129R-hPRL (PRLR-A)17, and to the overexpression of the long 
and short isoforms of PRLR. We also performed bioinformatics analysis of PRL and PRLR transcriptomic data 
from GII-III and GBM patients and its correlation with survival. Our findings suggest that the activation of the 
PRL/PRLR pathway may facilitate GBM tumour progression.
Results
pRL and pRLR are expressed in GBM cells. We evaluated the expression of PRL in human and rodent 
GBM cells by immunofluorescence. Human (U251-MG, U87-MG, U373-MG) and rat (C6) GBM cells presented 
PRL staining (Fig. 1A). We also assessed the content of PRL in cell protein extracts and supernatants from rat 
and human GBM cells by radioimmunoassay (RIA). While PRL was detected in the supernatant of C6 GBM 
cells (6–22 ng/ml), PRL levels in the supernatant of U251-MG cells were under the detection threshold. In C6 
cell extracts PRL content was between 23.4–38.2 ng/ml, whereas in U251 it was between 0.1 and 0.6 ng/ml. These 
expression levels are not uncommon for extrapituitary tissues producing PRL, in which local PRL levels are usu-
ally below detection limits18. The expression of PRL was also evaluated in U251-MG human GBM xenografts 
growing in the brain of nude mice. PRL+ cells were readily detected in tumour cells within the tumour mass as 
well as in those infiltrating the non-neoplastic brain parenchyma (Fig. 1B).
PRLR expression was detected in human U251-MG cells by immunofluorescence (Fig. 2A). Since there are 
several isoforms of PRLR with distinct downstream mechanisms, we assessed their expression in GBM cells 
by WB (Fig. 2B, Supp. Fig. S1). We detected expression of PRLR in human (U251-MG, LN229), mouse (GL26) 
and rat (C6) GBM cells. While the long PRLR isoform was detected in cells from all species studied, other 
bands that presumably corresponded to intermediate and short PRLR isoforms were only observed in human 
GBM cells.
pRLR pathway activation enhances proliferation, chemoresistance and migration of GBM 
cells. We assessed the effect of PRLR pathway activation or blockade on proliferation, viability and chemosen-
sivity of GBM cells. Addition of PRL (100 ng/ml) stimulated the proliferation of human U251-MG and U373-MG 
GBM cells (Fig. 3A). However, cell viability was not affected by the incubation with PRL in U87-MG and 
U373-MG, nor in GL26 mouse GBM cells (Fig. 3B). The cytotoxic effect of chemotherapeutic drug cisplatin on 
the viability of U251-MG human GBM cells was partially impaired by concomitant treatment with PRL (Fig. 3C). 
A similar effect was observed when cell death was induced by temozolomide (TMZ, Fig. 3D). Treatment with 
cisplatin also inhibited the clonogenic response of rat C6 GBM cells, an effect that was inhibited by the presence 
of PRL (Fig. 3E). On the other hand, PRLR blockade using antagonist ∆1–9-G129R-hPRL (PRLR-A, 2.5 µg/ml) 
significantly reduced the proliferation rate of U373-MG and U251-MG cells (Fig. 3F), as well as the viability of 
U87-MG, U373-MG and GL26 cells (Fig. 3G). In addition, PRLR-A increased the cytotoxic effect of cisplatin in 
U251-MG cells (Fig. 3H).
We next evaluated the effect of PRL, PRLR or PRLR-A overexpression on the viability and chemosensitivity 
of GBM cells. While the transfection of U251-MG GBM cells with a plasmid encoding human PRL resulted 
in increased viability and reduced cytotoxic effect of cisplatin, transfection with a plasmid encoding PRLR-A 
reduced GBM cell viability and boosted the sensitivity to cisplatin (Fig. 4A). On the other hand, transfection of 
GL26 GBM cells with plasmids encoding the long or short isoforms of murine PRLR did not directly affect their 
viability, but both inhibited the cytotoxic effect of cisplatin, as assessed by MTT assay (Fig. 4B). Furthermore, the 
cytotoxic effect of cisplatin on the clonogenic response of C6 cells was partially impaired by the overexpression of 
the short (Fig. 4C) and long (Fig. 4D) isoforms of rat PRLR.
In order to evaluate whether PRLR was involved in cell migration as suggested by a previous study12, we evalu-
ated the migration of GBM cells in a scratch assay. We observed that the blockade of PRLR using PRLR-A delayed 
wound healing in rat (C6, Fig. 5A) and human (LN229, Fig. 5B) GBM cells. Considering that the ability of tumour 
cells to migrate requires the activation of matrix metalloproteinases (MMP)19, we evaluated whether the activity 
of MMPs in GBM cell culture supernatant was stimulated by PRL. We found that MMP-2 was more abundant 
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than MMP-9 in the cell supernatant of both rat and human GBM cells. PRL increased the content of activated 
MMP-2 in rat (C6; Fig. 5C,E; Supp. Fig. S2) and human (U251-MG; Fig. 5D,F; Supp. Fig. S3) GBM cell culture 
media. While MMP-9 was below detection threshold in treated and untreated rat GBM cell media, the addition of 
PRL increased the content of MMP-9 in human GBM cell conditioned media (Fig. 5D,F; Supp. Fig. S3).
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Figure 1. Expression of prolactin in experimental glioblastoma multiforme. (A) Representative low and 
high magnification microphotographs show PRL expression in human (U87-MG, U251-MG and U373-MG, 
green staining) and rat (C6, red staining) GBM cell lines, as assessed by immunofluorescence using specific 
antibodies against human and rat PRL. Insets show representative negative controls and a positive control 
(somatolactotrope GH3 cells). Nuclei were stained with DAPI. The percentage of PRL+ cells (and confidence 
intervals) for each of the cell lines are depicted on the right side of each panel. (B) Human PRL expression 
(green fluorescence) was assessed in brain sections from nude mice bearing intracranial U251-MG human 
GBM xenografts. A representative field is shown. NNB: non-neoplastic brain. Arrows indicate PRL+ tumour 
cells.
4Scientific RepoRtS |         (2019) 9:19578  | https://doi.org/10.1038/s41598-019-55860-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
PRL and PRLR expression in GII-III and GBM patients. We next aimed to evaluate the expression of 
PRL and PRLR in human glioma samples. Meta-analysis of transcriptomic data from the TCGA revealed that 
PRLR is present in virtually all GII-III and GBM samples (Fig. 6A, Supp. Fig S4). PRL mRNA was detected in 
12% of GII-III samples (65/530) and in significantly more GBM samples, with 30% of positive biopsies (45/150; 
Fig. 6B; Supp. Fig. S4). The levels of PRLR mRNA were similar in GII-III and GBM samples (Fig. 6C), while PRL 
mRNA levels were higher in GBM than in GII-III samples (Fig. 6D). Furthermore, in PRL-expressing GBM 
samples, PRLR mRNA expression levels had a significant correlation with PRL and also with MMP-2 mRNA 
expression levels (Fig. 6E,F).
When we examined the survival of glioma patients according to the local expression of PRL or PRLR we found 
no significant changes, neither in the overall survival of PRL+ vs. PRL− GII-III or GBM patients (Fig. 7A,C), 
nor in the overall survival of PRLRHIGH vs. PRLRLOW (Fig. 7B,D). However, the long-term survival rates of both 
GII-III and GBM patients that were PRL+ were lower than those with PRL- tumours (Fig. 7E,F). In addition, 
glioma patients with PRLRHIGH tumours exhibited lower long-term survival than those with PRLRLOW tumours 
(Fig. 7E,F).
The incidence of glioma has been reported to be significantly higher in male than in female patients20. This 
was also observed in the TCGA database that we analysed, where 55% GII-III patients (291/530) and 65% GBM 
patients (97/150) were males (Supp. Fig. S6A,B). No differences were observed in the median survival of female 
vs. male GII-III patients (F: 94.5 mos.; M: 81.1 mos.) or GBM patients (F: 14 mos.; M: 14 mos.) (Supp. Fig. S6C). 
The expression levels of PRLR mRNA did not show significant differences between GII-III and GBM patients in 
both cohorts of patients (Fig. 8A; Supp. Fig. S8A). The percentage of PRL+ samples in GII-III and GBM patients 
was similar between men [GII-III/PRL+: 12% (8–16%); GBM/PRL+: 28% (19–38%)] and women [GII-III/PRL+: 
13% (9–18%); GBM/PRL+: 23% (12–36%)] and the upregulation of PRL mRNA levels in GBM with respect to 
GII-III samples was found in both female and male patients (Fig. 8B; Supp. Fig. S8B). However, the positive 
correlation between PRL and PRLR mRNA levels was only observed in female GBM patients (Fig. 8C,D; Supp. 
Fig. S9). We then analysed the survival of male PRL+ GII-III and GBM patients depending on their expression of 
PRLR (Fig. 8E,F). We found that male GBM patients that expressed high levels of PRLR exhibited worse survival 
(MS: 10.5 mos.) than those with low levels of PRLR (26.7 mos.) (Fig. 8F). Interestingly, we observed that male 
GII-III patients that expressed low levels of PRLR performed worse (MS: 37.98 mos.) than those with high PRLR, 
all of which were alive by month 100th (Fig. 8E). While in female GII-III patients we did not observe differences 
depending on the expression of PRLR, there was a substantial decrease in the survival of female GBM patients 
with PRL+/PRLRLOW vs. PRL+/PRLRHIGH, i.e. 6.6 mos. vs. 25.9 mos., respectively (p = 0.06, Log Rank test) (Supp. 
Fig. S7). This is an interesting observation as it is opposed to what we observed in male patients. Nevertheless, 
larger samples of female GBM specimens are required to draw conclusions on the correlation of PRLR with the 
survival of this subgroup of patients.
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Figure 2. Expression of prolactin receptor in glioblastoma multiforme cells. (A) A representative 
microphotograph shows PRLR expression in human U251-MG GBM cells, as assessed by immunofluorescence 
using a specific anti-human PRLR (green fluorescence). (B) A representative blot shows PRLR isoforms, as 
evaluated by WB in protein extracts from human (U251-MG, LN229), mouse (GL26) and rat (C6) GBM cells.
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Discussion
In this study we showed that PRL and PRLR were expressed by GBM cell lines and facilitated their viability, 
proliferation, clonogenicity, migration and chemoresistance. We detected PRL and PRLR protein expression in 
all GBM cell lines evaluated. PRL expression was also detected in human GBM xenografts, which was notorious 
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Figure 3. Effect of prolactin or its receptor blockade on proliferation, viability and chemoresistance of 
glioblastoma multiforme cells. (A) Human U251-MG and U373-MG GBM cells were incubated for 6 h with 
PRL (100 ng/ml) and proliferation was evaluated by BrdU incorporation ELISA. *p < 0.05 vs. respective control 
(Student’s t test). (B) The viability of U87-MG, U373-MG and GL26 cells was assessed 72 h after incubation with 
PRL by MTT assay. (C) U251-MG cells were incubated with PRL and cisplatin (5 µM) for 72 h. Cell viability was 
evaluated by MTT assay. *p < 0.05 vs. respective control without PRL, ^p < 0.05 vs. respective control without 
cisplatin (ANOVA). (D) U251-MG cells were incubated with PRL and TMZ (15 µM) for 72 h. Cell viability 
was evaluated by MTT assay. *p < 0.05 vs. respective control without PRL, ^p < 0.05 vs. respective control 
without TMZ (ANOVA). (E) Rat GBM cells (C6) were incubated with PRL and 16 h later they were treated with 
cisplatin (1 µM) for additional 24 h. Cells were then processed for the clonogenic assay. *p < 0.05 vs. respective 
control without PRL (ANOVA). (F) U251-MG and U373-MG GBM cells were incubated for 6 h with PRLR-A 
(∆1–9-G129R-hPRL, 2.5 µg/ml) and proliferation was evaluated by BrdU incorporation ELISA. *p < 0.05 vs. 
respective control (Student’s t test). (G) The viability of U87-MG, U373-MG and GL26 cells was assessed 72 h 
after incubation with PRLR-A by MTT assay. *p < 0.05 vs. respective control (Student’s t test). H) U251-MG 
cells were incubated with PRLR-A and cisplatin (5 µM) for 72 h. Cell viability was evaluated by MTT assay. 
*p < 0.05 vs. respective control without PRLR-A, ^p < 0.05 vs. respective control without cisplatin (ANOVA).
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in tumour cells infiltrating the non-neoplastic brain tissue. We observed homogenous expression of PRLR in 
U251-MG cells by immunofluorescence and WB, which revealed that human GBM cells express long, short and 
intermediate isoforms of PRLR, while rodent GBM cells seemed to express mainly the long isoform. PRLR was 
previously detected in U87-MG12,21 and U251-MG GBM cells12 and primary cultures of human GBM cells21. 
However, to best of our knowledge this is the first report depicting the isoforms of PRLR in GBM cells.
Invasion is a feature of GBM that plays a central on the pathogenesis of this tumour and seems to be involved 
in its high rate of recurrence. In agreement with previous reports from Alkharusi et al.12, our findings indicate 
that PRL facilitates GBM cell migration. Here we observed that PRL stimulation upregulates the activity of two 
matrix metalloproteinases (MMP-2 and MMP-9) in GBM cells, which are involved in tumour cell invasion and 
epithelial-to-mesenchymal transition (EMT)22–25. Wang et al.23 have shown a positive correlation between MMP-2 
and MMP-9 expression and the malignancy of this tumour. A recent study showed that MMP-9 overexpression 
also promotes cell growth and increases the clonogenicity of human GBM cells26. Taken together, these findings 
suggest that PRL and PRLR would contribute to GBM cell migration, invasion and clonogenicity, partially by 
the modulation of MMP-2 and MMP-9 expression. In fact, analysis of transcriptomic data indicated that PRLR 
expression is positively correlated with the levels of MMP-2 expression in tumour samples from GBM patients.
Our results show that the activation of the PRL/PRLR pathway enhanced GBM cells chemoresistance to cis-
platin and temozolomide. This process was already observed in hormone-dependent tumours, such as breast and 
prostate cancer3,8,27–29. PRL was found to abrogate cisplatin binding to DNA and to increase the sequestration of 
cisplatin in the cytoplasm by the glutathione-S-transferase8, whereas a PRLR antagonist sensitized T47D breast 
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Figure 4. Effect of the overexpression of prolactin, its receptor or the receptor antagonist on the response of 
glioblastoma multiforme cells to chemotherapy. (A) Human U251-MG GBM cells were transfected for 6 h with 
plasmids encoding human PRL (pPRL) or PRLR-A (pPRLR-A). 16 h later, they were incubated with cisplatin 
(5 µM) for 72 h. Cell viability was then evaluated by MTT assay. (B) Mouse GL26 GBM cells were transfected 
for 6 h with plasmids encoding the short (pSPRLR) or the long (pLPRLR) isoforms of the mouse PRLR. 16 h 
later, they were treated with cisplatin (2 µM) for 72 h. Cell viability was assessed by MTT. *p < 0.05 vs. respective 
control plasmid (pCTRL), ^p < 0.05 vs. respective control without cisplatin (ANOVA). C-D) Rat GBM cells 
(C6) were transfected for 6 h with plasmids encoding the (C) short (pSPRLR) or the (D) long (pLPRLR) 
isoforms of the rat PRLR. 16 h later, they were incubated with cisplatin for additional 24 h. Cells were then 
processed for the clonogenic assay. *p < 0.05 vs. respective pCTRL, ^p < 0.05 vs. respective control without 
cisplatin (ANOVA).
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Figure 5. Effect of prolactin receptor blockade on glioblastoma multiforme cell migration. (A) Rat (C6) and (B) 
human (LN229) GBM cells were cultured until confluence with PRLR-A (2.5 µg/ml). A scratch was performed 
in the monolayer and the scratch area was measured at different time points. *p < 0.05 vs. control (Non-lineal 
regression analysis). Each dot indicates the mean ± SEM of 2 wells. The graphs shown are representative of 3 
experiments. (C,D) SDS-PAGE gelatine zymography of conditioned media from (C) rat and (D) human GBM 
cells incubated in the presence of PRL (100 ng/ml) for 48 h. Gels were stained with Coomassie blue and bands 
were analysed by densitometry with ImageJ software. Zymographic activity was expressed as percentage in 
relation to a standard internal sample that saturates at a density of 50%. *p < 0.05 (Student’s t test). Bars depict 
the mean ± SEM of 6 wells. The graphs shown are representative of 2 experiments. (E,F) Representative gels are 
shown.
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tumour cells to cisplatin30. Jak2/STAT5, the main signalling cascade activated by PRLR, and other cascades also 
triggered by PRLR, including MAPK (ERK1/2) and PI3K/Akt, have been linked to the pro-tumourigenic effects of 
PRL in hormone-dependent tumours, including cell proliferation, invasion, migration and chemoresistance3. In 
fact, STAT5 promotes the amplification of treatment-resistant prostate stem/progenitor cells, predicts early cancer 
recurrence and favours metastatic dissemination3. According to Alkharusi et al.12, PRLR activation also induces 
STAT5 phosphorylation in GBM cells, a mechanism that has been involved in tumour cell migration12. STAT5 
pathway, which is the canonical pathway for long PRLR signalling31, was reported to be over-activated in GBM 
and directly involved in the modulation of proliferation, cellular transformation, migration and apoptosis32–34. 
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Figure 6. Transcriptomic analysis of prolactin and its receptor in human glioma. Meta-analysis of 
transcriptomic data from GII-III (n = 530) and GBM (n = 150) (The Cancer Genome Atlas): (A,B) % of samples 
expressing (A) PRLR mRNA or (B) PRL mRNA in GII-III (65/530) and GBM (45/150). * p < 0.05, χ2 test. 
(C,D) Dot plots showing the normalized expression of (C) PRLR mRNA levels and (D) PRL mRNA levels. 
*p < 0.05, Mann-Whitney U test. (E,F) Spearman correlation between (E) PRL and PRLR or between (F) 
MMP-2 and PRLR, in PRL+ GBM samples.
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Blockade of PRLR using different antagonists in GBM cells efficiently inhibited the phosphorylation of STAT512,35. 
PRL was also reported to stimulate Ca2+ entry and its intracellular mobilization in GBM cells, together with a 
dose-dependent increase of GBM cell proliferation and viability21.
Studies evaluating the expression of PRL and PRLR in human GBM have generally analysed a small num-
ber of samples. However, the expression of these proteins has been consistently detected by immunofluores-
cence in 19%36, 25%10 and 47%11 of GBM biopsies. These figures are in agreement with the transcriptomic data 
that we analysed, which indicated that 30% of 150 GBM patients express PRL mRNA. PRLR was also detected 
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Figure 7. Survival of grade II-III glioma and glioblastoma multiforme patients according to the local 
expression of prolactin and its receptor. Meta-analysis of transcriptomic data from The Cancer Genome Atlas: 
(A,B) Kaplan-Meier survival curves of GII-III patients depending on the (A) tumour expression of PRL or 
(B) PRLR tumour expression levels (PRLRHIGH: 75% percentile; PRLRLOW: 25% percentile); (C,D) Kaplan-
Meier survival curves of GBM patients depending on the (C) tumour expression of PRL or (D) PRLR tumour 
expression levels. (E,F) Tables show the median survival (MS), long-term survival and sample size of (E) GII-III 
and (F) GBM patients.
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by immunohistochemistry in GBM samples ranging from 44%36 to 66%12. Our analysis of transcriptomic data 
from GBM samples indicates that virtually all tumours express PRLR mRNA. In addition to the local detection 
of PRL and PRLR, hyperprolactinemia was also reported in 36%11 and 44%36 of GBM patients. Authors high-
lighted the fact that the proportion of hyperprolactinemia was twice as high in men as in women harbouring 
brain tumours, which opposes what happens in the general population, in which hyperprolactinemia is more 
frequent in women36, and reinforces the idea of sexual dimorphism in GBM pathogenesis. The development of 
hyperprolactinemia in GBM patients has also been proposed to be related to the irradiation of the hypothalamus 
during GBM treatment in a recent report that detected hyperprolactinemia in 32–35% of female and 66% of male 
patients37. Nevertheless, this growing body of evidence suggests that circulating levels of PRL should be closely 
monitored in glioma patients.
It has been proposed that the detection of PRL by immunohistochemistry in GBM specimens but not by 
real-time PCR indicates that the presence of PRL in primary tumours may not be a reflection of local production, 
but rather of circulating PRL that access the tumour10. However, the detection of PRL mRNA by GBM samples 
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Figure 8. Transcriptomic analysis of prolactin and its receptor expression in glioma from female and male 
patients. Meta-analysis of transcriptomic data from female and male patients bearing GII-III or GBM (The 
Cancer Genome Atlas): (A,B) Dot plots showing the normalized expression of (A) PRLR mRNA levels and (B) 
PRL mRNA levels. *p < 0.05 vs. corresponding GII-III (Mann-Whitney U test), (C,D) Spearman correlation 
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sequencing suggests that local production of PRL accounts, at least in part, for the presence of this hormone in 
GBM. Intracellular PRL has been shown to correlate with a high proliferation index in GBM biopsies, an effect 
that was associated with a mitogenic effect of this hormone36. Our findings using PRL and plasmids encoding 
PRL, which mimic the local expression of this hormone, suggest that PRL may exert a direct mitogenic effect in 
GBM cells. Moreover, male GBM patients that express local PRL and high levels of PRLR exhibited significantly 
worse overall survival than those with low local expression levels of PRLR. This finding supports the notion that 
local PRL/PRLR system plays a role in the pathogenesis of GBM facilitating tumour progression. In addition, 
while PRLR mRNA was present in virtually all GII-III and GBM biopsies at comparable levels, PRL mRNA 
expression was upregulated in GBM samples. This upregulation in PRL expression according to glioma grade was 
also observed when we stratified patient populations by their biological sex. Interestingly, the positive correlation 
between PRL and PRLR mRNA levels was only observed in female PRL+ GBM patients, suggesting that a positive 
feedback between these proteins may underlie sexual dimorphism. The sexual dimorphism in the incidence of 
GBM has been extensively reported, with a male/female ratio of ~1.620, which is in agreement with the distribu-
tion of patients in the database we analysed (65% male vs. 35% female). Although we did not detect differences 
in the survival of male and female patients, a recent report indicates that the 5-year cancer-specific survival rate 
of female patients is significantly higher than in males38. This is in agreement with a recent report indicating that 
sexual dimorphism may also govern the response to treatment, as they observed that standard therapy is more 
effective in female GBM patients39.
Reproductive hormones have been proposed to influence the occurrence of GBM in the female population. A 
multi-centre study showed that the risk of developing glioma within the female population fluctuated with age at 
menarche, age at first parturition and hormonal contraceptive use40. While a case-control study found increased gli-
oma risk in nulliparous women in comparison with parous women41, another study indicated that pregnancy was 
associated with tumour progression in female patients harbouring grade II-III, but not grade I tumours42. Long terms of 
breast-feeding were found to increase the risk of developing glioma when compared to shorter breast feeding periods41. 
Although circulating PRL may play a role in the pathogenesis of GBM, expression of PRL and PRLR in the tumour 
microenvironment may exert autocrine/paracrine effects that modulate GBM cell behaviour. Unfortunately, due to the 
relatively small number of female patients with PRL+ GBM, we could not perform a statistical analysis with enough 
power to conclusively compare the survival of female patients harbouring PRL+/PRLRHIGH and PRL+/PRLRLOW GBM. 
Nevertheless, the data shown here suggest that female patients with PRL+/PRLRHIGH GBM live longer than those with 
PRL+/PRLRLOW GBM. An opposite scenario was observed in the male PRL+ GBM population, in which the upregula-
tion of PRLR was associated to a significant reduction in the median survival when compared to patients with PRLRLOW 
GBM, who exhibited a striking 17-mos. difference in median survival.
Hormonal differences do not fully explain the differences between male and female GBM patients. It was 
previously reported that biological sex-specific differences in brain tumour rates are comparable at all ages, which 
implies that factors other than sex hormones are involved in these differences43. Sun et al.43 proposed that males 
are at higher risk of developing GBM due to an intrinsic sexual dimorphism in astrocyte transformation, as male 
GBM astrocytes exhibit higher proliferation rates, greater inactivation of the retinoblastoma tumour suppressor 
protein (RB), as well as increased tumourigenesis in vivo than female GBM astrocytes. Taken together, these 
results suggest that a proper treatment assignation according to biological sex differences may improve the care 
of GBM patients.
PRL was detected in a smaller percentage of GII-III patients and at lower expression levels than in GBM 
patients. Interestingly, we observed that male patients harbouring GII-III expressing PRL and high levels of 
PRLR had better survival than patients with low levels of PRLR. Strikingly, all male patients with PRL+/PRLRHIGH 
GII-III were alive by month 100th. This result opposes our findings in GBM patients, but suggests that PRL and 
PRLR may hold value as therapeutic targets and/or prognostic biomarkers in both GII-III and GBM patients. 
Newly developed models of lower grade glioma44 may contribute to understand the role of PRL/PRLR in GII-III. 
Contradictory results on the role of PRL/PRLR have been also reported in hormone-dependent tumours. 
Although PRLR signalling has been traditionally involved in tumourigenesis of the mammary gland, it has been 
recently associated to the inhibition of breast cancer invasion, and a protective role of PRLR/STAT5 signalling 
has been proposed in already established tumours3. STAT5 activation seems to be necessary at the early stages 
of breast cancer and its phosphorylation seems to be lost during cancer progression (for a review see3). In fact, 
PRLR/STAT5 pathway has been shown to counteract EMT in human breast cancer cells hence to maintain them 
in a more differentiated, less aggressive state45. Summarizing, PRL/PRLR signalling may elicit very different out-
comes depending on the biological sex of the patient and glioma grade, factors that need to be taken into consid-
eration before translating therapies using PRLR antagonists to the neuro-oncology clinic.
In this study we detected PRL and PRLR expression across all GBM cell lines tested and showed that PRL/
PRLR pathway is involved in their survival and response to chemotherapy. Even though GBM cell lines are com-
monly used by many researchers in translational neuro-oncology46–51, there are many publications that call into 
question the legitimacy of these in vitro models52,53. The utilization of serum in media may change the phenotype 
and/or genotype of GBM cell lines and cause depletion of stem cell-like tumour cells53,54. Furthermore, the injec-
tion of these cells for in vivo GBM models may fail to accurately mirror important morphological features of the 
tumour53–57. Additionally, differences between serum batches can disrupt reproducibility58. Therefore, glioma 
neurospheres59–61, annotated and validated cell lines derived from surgical samples of GBM patients53,55,59,62 and 
other serum-free cell cultures54 should be considered for future prospects in order to perform experiments that 
reflect more realistically the gliomas’ microenvironment. Moreover, further development of lower grade glioma 
models is required to clarify why the activation of PRL/PRLR signalling elicit opposite outcomes between GII-III 
and GBM patients. Our study proposes PRLR as a therapeutic target for the treatment of GBM and warrants 
further evaluation of PRL and PRLR as prognostic biomarkers in glioma patients. Our work provides additional 
evidence to the notion that sexual dimorphism should be taken into account to improve the care of GBM patients.
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Methods
patients and datasets. RNA-Seq expression data of PRL, PRLR and MMP-2 (Illumina HiSeq 2000 RNA 
sequencing platform) from 530 GII-III samples and 150 GBM samples were obtained from The Cancer Genome 
Atlas (TCGA) and analysed using UCSC Xena browser (https://doi.org/10.1101/326470)63. This database pro-
vides quantitative gene expression information and a compelling list of patients’ characteristics, including their 
clinical parameters and survival rates (Supp. Fig. S5).
Drugs. Dulbecco’s Modified Eagle’s Medium (DMEM; 12800017), Penicillin-Streptomycin, Trypsin-EDTA 
(0.05%) and Lipofectamine 2000 were obtained from Gibco (Invitrogen, Carlsbad, CA); fetal bovine serum 
(FBS) and horse serum (HS) from Natocor (Córdoba, Argentina); cisplatin from Microsules (Buenos Aires, 
Argentina); and temozolomide and ovine prolactin from Sigma (St. Louis, MO). OCT medium for frozen sec-
tions was obtained from Biopack (Buenos Aires, Argentina). Ketamine was obtained from Holliday (Argentina 
Poniente, Mexico). Xylazine (Kensol) was obtained from König (Buenos Aires, Argentina). Ketoprofen 
(Ketofen) was from Merial Laboratories S.A. (Buenos Aires, Argentina). Anti-rat PRL is from Dr. A. Parlow, 
National Hormone and Pituitary Program (NHPP; Torrance, CA). The PRLR antagonist ∆1–9-G129R-hPRL 
was produced by recombinant technology and purified by ion exchange chromatography as previously 
described17. Anti-human PRL (A0569) was obtained from Dako (Santa Clara, CA) and anti-human PRLR 
antibodies for WB and immunocytochemistry (H-300 and D-7) are from Santa Cruz Biotechnology (Dallas, 
TX). Anti-rabbit IgG and anti-rabbit fluorescein-conjugated secondary antibody are from Vector Laboratories 
Inc. (Burlingame, CA). Anti-guinea pig rhodamine-conjugated secondary antibody is from Chemicon 
International (Temecula, CA).
cell culture. GBM cell lines were grown in Petri dishes containing DMEM with high glucose, L-glutamine, 
sodium pyruvate and sodium bicarbonate, supplemented with 10% SFB and 1% Penicillin-Streptomycin. Cells 
were harvested using Trypsin-EDTA (0.05%) in PBS and counted with Trypan-blue. For in vitro experiments, 
cells were grown with 5% HS in order to avoid any possible interaction between bovine PRL from FBS and 
cells’ PRLR. For the experiments, the doses of PRL (100 ng/ml)8,12,21,64–66 and PRLR-A (2.5 µg/ml)7,17,18,67–70 were 
obtained from previous publications. Dose selection for cisplatin and TMZ can be found in Supp. Fig. S10.
Animals. Adult female athymic N:NIH Swiss mice (6–8 week old) were purchased at the vivarium of Facultad 
de Ciencias Veterinarias, Universidad Nacional de La Plata, Argentina, and kept in controlled conditions of light 
(12 h light-dark cycles) and temperature (20–25 °C). Mice were fed with standard lab chow and water ad libitum 
and all efforts were made to minimize distress. All animal work was conducted according to the NIH guidelines 
and was approved by the Institutional Ethical Committee (Comité Institucional para el Cuidado y Uso de Animales 
de Laboratorio, CICUAL), Facultad de Medicina, Universidad de Buenos Aires; approval ID: Res. (CD) N° 697/19.
Brain tumour models. Nude intracranial tumour models were generated as previously described71. Briefly, 
mice were anesthetized with ketamine (100 mg/kg) and xylazine (15 mg/kg) and placed in a stereotactic appara-
tus modified for mice. Human U251-MG GBM cells (1.5 × 106 cells) were injected in a volume of 5 µl unilaterally 
into the right striatum (+0.5 mm AP; −2.1 mm ML; −2.9, −3.2, −3.5, −3.8, −4.1 mm DV from bregma) using 
a 5 µl Hamilton syringe with a 33-gauge needle. Mice received ketoprofen analgesic (4 mg/kg) the day of the sur-
gery and the next day. 35 days after injection, mice were perfused using Tyrode’s buffer and 4% paraformaldehyde 
(PFA) and brains were collected immediately and processed for immunohistochemistry.
immunocytochemistry. After perfusion, brains were post-fixed for 72 h in 4% PFA, washed with PBS, 
soaked in cold 20% sucrose overnight, frozen to −70 °C with 2-methylbutane (isopentane) in a dry ice/acetone 
bath, and finally sectioned in cryostat using OCT freezing media. Tumour cells seeded in coverslips were fixed 
with 4% PFA for 10 min on ice and washed with PBS. For immunocytochemistry against rat and human PRL, 
cells were permeabilized in citrate buffer (pH 6) at 350 W for 7 min., followed by washing during 5 min. with TBS- 
0.5% Triton- 0.1% Azide. Blockade was performed in TBS- 0.2% Triton- 0.1% Azide- 10% goat serum for 1 h and 
incubation with antibodies against rat PRL (NHPP) or human PRL (A0569, Dako) was performed overnight in 
TBS- 0.2% Triton- 0.1% Azide- 1% goat serum. Immunocytochemistry for human PRLR was performed with-
out citrate buffer permeabilization. Brain sections and cells were blocked with PBS- 10% goat serum for 1 h and 
incubation with antibody against human PRLR (sc-20992, Santa Cruz Biotechnology) was performed overnight 
in PBS− 1% goat serum. Then, cells and tissues were incubated with their respective fluorescent secondary anti-
bodies, anti-guinea pig (Chemicon International) or anti-rabbit (Vector Laboratories), for 1.5 h. After washing 
with distilled water, cells and tissues were incubated with DAPI for 10 min, washed and mounted on slides using 
Vectashield (Vector Laboratories). Negative controls were incubated without the primary antibodies. For the 
immunocytochemistry of PRLR, somatolactotrope GH3 cells were used as the positive control. The specificity of 
the antibodies used here was previously reported for PRLR72 and PRL73.
Western Blot (WB). Total proteins were extracted from GBM cell lines’ cultures with NP-40 lysis buffer con-
taining 150 mM NaCl, 50 mM Tris Base (pH 8), 1% Triton X-100 in water, and a protease inhibitor cocktail (1/100; 
P8340, Sigma). Following centrifugation at 12,000 g for 40 min, the supernatant was recovered. Protein concen-
tration of each sample was determined by Bradford protein assay (Bio-Rad Laboratories, Hercules, CA). 40 µg of 
protein were size-fractionated in 12% SDS-polyacrylamide gel and then electrotransferred to polyvinyl difluoride 
(PVDF) membranes. Correct protein loading and transfer efficiency were assessed by membrane staining with 
red Ponceau. Blots were blocked for 120 min in 5% non-fat dry milk- PBS- 0.1% Tween 20 at room temperature 
and incubated overnight at 4 °C with anti-PRLR antibody (H300, 1/250, and D7, 1/200; Santa Cruz) in the same 
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buffer. After washing, membranes were incubated for 1 h with HRP-conjugated anti-rabbit (1/1000; Millipore, 
Cat# AP103P) or anti-mouse antibody (1/1000; Millipore, Cat# AP130P) in 5% non-fat dry milk- PBS- 0.1% 
Tween 20. Blots incubated in the absence of primary antibody were used as negative controls. Immunoreactivity 
was detected by enhanced chemiluminescence (Productos Bio-Lógicos, Argentina) in a chemoluminiscence 
imaging system (G Box Chemi HR16, Syngene; Cambridge, UK).
pRL radioimmunoassay. PRL was measured in C6 and U251-MG cell extracts and supernatants. Cells were 
seeded in 24-well plates and cultured in 200 μl/well for 48 h. Then, supernatants were collected and cell proteins 
were extracted as described above. PRL levels were measured by RIA using reagents provided by the National 
Institute of Diabetes and Digestive and Kidney Diseases, National Hormone and Pituitary Program (Torrance, 
CA) as previously described69.
BrdU incorporation assay. Human GBM cells were incubated with 100 ng/ml ovine PRL or 2.5 µg/
ml PRLR-A for 6 h. Then, cells were incubated with 10 µM BrdU labelling solution for the last 1.5 h and BrdU 
incorporation into cellular DNA strands was assessed by ELISA following manufacturer’s instructions (Roche 
Molecular Biochemicals, Mannheim, Germany; Cat# 11647229001) as previously described74. Absorbance was 
measured in 96-well plate spectrophotometer (Bio-Rad, Model 550) at 450 nm.
transfections. Human U251-MG cells were seeded in 24-well plates and 24 h later were transfected for 6 h 
with plasmids encoding human prolactin (pPRL) under the control of the cytomegalovirus (CMV) promoter 
or encoding the PRLR-A (pPRLR-A) under the control of the metallothionein promoter75, using Lipofectamine 
2000 (Invitrogen) following the indications of the supplier. Controls were incubated with an empty pcDNA3 plas-
mid (pCTRL). After 16 h, 5 µM cisplatin was added to the incubation media for additional 72 h, and cell viability 
was finally assessed by MTT assay.
Mouse GBM GL26 cells were transfected as described above with plasmids encoding the short (pSPRLR) or 
the long (pLPRLR) isoforms of the mouse PRLR under the control of the EF1 promoter that were kindly donated 
by Dr Julia Halperin (Universidad Maimonides, Buenos Aires, Argentina)76,77. 2 µM cisplatin was added to the 
incubation media for additional 72 h, and cell viability was finally assessed by MTT assay. Rat GBM C6 cells were 
transfected with plasmids encoding the short (pSPRLR) or the long (pLPRLR) isoforms of the rat PRLR under 
the control of the CMV promoter78. After 16 h, cells were incubated with 1.5 µM cisplatin and processed for MTT 
or clonogenic assays.
cell viability assay (Mtt). Cell viability was analysed using 3-(4,5-dimethylthiazol-2-yl)−2,5-diph
enyltetrazolium bromide (MTT; Molecular Probes, Invitrogen) as described before74. Absorbance was deter-
mined using a 96-well plate spectrophotometer (Bio-Rad, Model 550) at 595 nm.
clonogenic assay. After transfecting rat GBM C6 cells with pCTRL, pSPRLR or pLPRLR, cisplatin (1.5 µM) 
was added to the medium for 24 h. Then, cells were harvested with trypsin and 450 cells were seeded in 6-well tis-
sue culture plates. Ten days later, cells were stained with Giemsa. The number of colonies containing a minimum 
of 50 cells (colony-forming unit, CFU) was counted under microscope.
Scratch assay. Rat GBM C6 cells and human GBM LN229 cells were seeded with or without PRLR-A in 
24-well plates for 24 h. A wound was then performed by scratching the confluent cell culture wells with a micro-
pipette tip. Afterwards, cells were washed with PBS and reincubated with or without PRLR-A in complete DMEM 
without serum. Lastly, cells were photographed at different time-points for up to 10 h and the wound area was 
measured using ImageJ Software.
Zymography. Rat C6 and human U251-MG GBM cells were incubated for 48 h in the presence of 100 ng/
ml PRL. Conditioned media was collected and MMP gelatinocytic activity was assessed by zymography. 3 μl of 
medium was loaded onto 10% acrylamide gel containing 0.2% gelatine and run at 120 V. Gels were then washed 
with 50 mM Tris-HCl pH 7.5 in 2.5% Triton X-100 for 45 min, followed by a 45 min washing step with a 50 mM 
Tris HCl solution containing 5 mM CaCl2 and 1 µM ZnCl2 plus 2.5% Triton X-100, pH 7.5. Gels were then incu-
bated for 24 h at 37 °C with a solution of 50 mM TrisHCl containing 10 mM CaCl2, 200 mM NaCl, pH7.5. Finally, 
gels were stained with 0.5% Coomassie Brilliant Blue R-250 and destained with decolorizing solution (25% v/v 
isopropanol plus 10% v/v acetic acid). Enzyme activity, seen as clear bands against a blue background was ana-
lysed by densitometry with ImageJ image processing system. The zymographic activity was expressed as a per-
centage in relation to a standard internal sample that saturates at a density of 50%. Data corresponding to different 
gels were normalized using internal control samples.
Statistical analysis. Data were graphed and analysed using GraphPad Prism version 5 software (GraphPad 
Software). All the data were tested for normality using the Kolmogorov Smirnoff test before performing para-
metric statistical tests. The data obtained using cell lines were normally distributed. Differences in BrdU incor-
poration, clonogenic ratio and MTT data were analysed by analysis of variance (ANOVA) followed by Tukey’s 
post-test. Differences in the expression levels of PRLR and PRL mRNA were assessed by Student’s t test, whereas 
the proportion of positive vs. negative patients was analysed by χ2 test. Nonlinear correlation analysis was used to 
analyse differences in the scratch assay. Correlation between PRL and PRLR expression was evaluated by Pearson 
analysis. Kaplan-Meier survival values were calculated for the low and high expression of PRL and PRLR. Overall 
survival between the groups was compared using log-rank test. Differences between groups were considered 
significant when p < 0.05. All the experiments were performed at least twice.
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